APA (7th ed.) Citation

Y, U., K, H., S, U., S, K., H, N., J, S., . . . Y, T. (2025). Discovery of the Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19. Journal of medicinal chemistry, 68(20), 21099. https://doi.org/10.1021/acs.jmedchem.5c00754

Chicago Style (17th ed.) Citation

Y, Unoh, et al. "Discovery of the Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19." Journal of Medicinal Chemistry 68, no. 20 (2025): 21099. https://doi.org/10.1021/acs.jmedchem.5c00754.

MLA (9th ed.) Citation

Y, Unoh, et al. "Discovery of the Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19." Journal of Medicinal Chemistry, vol. 68, no. 20, 2025, p. 21099, https://doi.org/10.1021/acs.jmedchem.5c00754.